Fasching PA

No ORCID on file · 52 papers in corpus · active 2005-2026

Study types

  • article 17
  • other 13

Condition tags

  • endometriosis 30
  • adenomyosis 3
  • chronic_pelvic_pain 3
  • dysmenorrhea 3
  • dyspareunia 2
  • infertility 1
  • die_deep_infiltrating 1
other 2026
Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology ·doi:10.1080/01443615.2026.2649743

BACKGROUND: Endometriosis is heterogeneous, and evidence for individualised postoperative management is limited. We assessed whether postoperative hormonal therapy exposure is associated with one-year changes in pain domains after first-tim…

2026
Geburtshilfe und Frauenheilkunde ·doi:10.1055/a-2717-7656

BackgroundFor the first time, an S3 guideline on complementary medicine in oncology was published in 2021, 2024 in May version 2.0 was published. The broad spectrum of complementary and integrative medicine was presented at the highest leve…

other 2025
Archives of gynecology and obstetrics ·doi:10.1007/s00404-025-08191-4

PURPOSE: Endometriosis appears in various forms and symptoms. With regard to the established endometriosis classifications, it is hardly possible to draw conclusions from the endometriosis to the symptoms caused by it. The objective of this…

2025
Gynecologic Oncology ·doi:10.1016/j.ygyno.2025.05.013

ObjectiveMany epithelial ovarian cancer (EOC) risk factors relate to sex hormones. The association between these factors and the expression of androgen receptor (AR), estrogen receptor-α (ER), and progesterone receptor (PR) in tumors is unk…

2024
Human genetics ·doi:10.1007/s00439-024-02707-9

Known risk loci for endometrial cancer explain approximately one third of familial endometrial cancer. However, the association of germline copy number variants (CNVs) with endometrial cancer risk remains relatively unknown. We conducted a …

2024
American journal of human genetics ·doi:10.1016/j.ajhg.2024.04.011

To identify credible causal risk variants (CCVs) associated with different histotypes of epithelial ovarian cancer (EOC), we performed genome-wide association analysis for 470,825 genotyped and 10,163,797 imputed SNPs in 25,981 EOC cases an…

other 2023
Gynecologic oncology ·doi:10.1016/j.ygyno.2022.10.018

OBJECTIVE: The presence of macroscopic residual disease after primary cytoreductive surgery (PCS) is an important factor influencing survival for patients with high-grade serous ovarian cancer (HGSC). More research is needed to identify fac…

2023
Journal of the National Cancer Institute ·doi:10.1093/jnci/djad011

BackgroundThe role of ovulation in epithelial ovarian cancer (EOC) is supported by the consistent protective effects of parity and oral contraceptive use. Whether these factors protect through anovulation alone remains unclear. We explored …

article 2023
International Journal of Gynecology & Obstetrics ·doi:10.1002/ijgo.15062

OBJECTIVE: To evaluate blood-based biomarkers to detect endometriosis and/or adenomyosis across nine European centers (June 2014-April 2018). METHODS: This prospective, non-interventional study assessed the diagnostic accuracy of 54 blood-…

2023
The journal of pathology. Clinical research ·doi:10.1002/cjp2.311

Our objective was to test whether p53 expression status is associated with survival for women diagnosed with the most common ovarian carcinoma histotypes (high-grade serous carcinoma [HGSC], endometrioid carcinoma [EC], and clear cell carci…

2023
Geburtshilfe und Frauenheilkunde ·doi:10.1055/a-2073-1887

In patients with existing ovarian function, there are some special aspects to adjuvant endocrine therapy in premenopausal patients with hormone receptor-positive, HER2-negative (HR pos./HER2 neg.) breast cancer. Treatment options include ta…

2022
Journal of the National Cancer Institute ·doi:10.1093/jnci/djac160

BackgroundKnown risk alleles for epithelial ovarian cancer (EOC) account for approximately 40% of the heritability for EOC. Copy number variants (CNVs) have not been investigated as EOC risk alleles in a large population cohort.MethodsSingl…

2022
European journal of human genetics : EJHG ·doi:10.1038/s41431-021-00987-7

Polygenic risk scores (PRS) for epithelial ovarian cancer (EOC) have the potential to improve risk stratification. Joint estimation of Single Nucleotide Polymorphism (SNP) effects in models could improve predictive performance over standard…

article 2021
Reproductive biomedicine online ·doi:10.1016/j.rbmo.2021.08.004

Research questionWhich is the optimal extraction method for isolating and quantifying circulating cell-free DNA (ccfDNA) from patients with endometriosis? Endometriosis is a common benign disease, associated with pain, infertility and reduc…

article 2021
Archives of gynecology and obstetrics ·doi:10.1007/s00404-021-06200-w

PURPOSE: In many diseases, it is possible to classify a heterogeneous group into subgroups relative to tumor biology, genetic variations, or clinical and pathological features. No such classification is available for endometriosis. In our r…

2020
British journal of cancer ·doi:10.1038/s41416-020-0900-0

BackgroundPTEN loss is a putative driver in histotypes of ovarian cancer (high-grade serous (HGSOC), endometrioid (ENOC), clear cell (CCOC), mucinous (MOC), low-grade serous (LGSOC)). We aimed to characterise PTEN expression as a biomarker …

article 2019
Journal of physiology and pharmacology : an official journal of the Polish Physiological Society ·doi:10.26402/jpp.2019.2.09

(P = 0.008) and magnesium (P = 0.043) compared to controls. This study confirms a high association of endometriosis and gastrointestinal disorders accompanied by an altered nutrient intake. A dietary intervention by a professional nutrition…

article 2019
Geburtshilfe und Frauenheilkunde ·doi:10.1055/a-0813-4411

Endometriosis is one of the most common benign gynecological diseases. The extremely heterogeneous complex of symptoms complicates the diagnosis and treatment of this disease. In most patients, there is a latency period of several years bet…

other 2018
The journal of pathology. Clinical research ·doi:10.1002/cjp2.109

We aimed to validate the prognostic association of p16 expression in ovarian high-grade serous carcinomas (HGSC) and to explore it in other ovarian carcinoma histotypes. p16 protein expression was assessed by clinical-grade immunohistochemi…

article 2017
Gynecologic oncology ·doi:10.1016/j.ygyno.2017.02.022

ObjectiveSeveral genetic variants have been validated as risk factors for ovarian cancer. Endometriosis has also been described as a risk factor for ovarian cancer. Identifying genetic risk factors that are common to the two diseases might …

other 2017
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology ·doi:10.1158/1055-9965.EPI-17-0367

Background: Comorbidities can affect survival of ovarian cancer patients by influencing treatment efficacy. However, little evidence exists on the association between individual concurrent comorbidities and prognosis in ovarian cancer patie…

2017
Nature genetics ·doi:10.1038/ng.3826

To identify common alleles associated with different histotypes of epithelial ovarian cancer (EOC), we pooled data from multiple genome-wide genotyping projects totaling 25,509 EOC cases and 40,941 controls. We identified nine new susceptib…

2016
Oncotarget ·doi:10.18632/oncotarget.10215

BackgroundRegulatory T (Treg) cells, a subset of CD4+ T lymphocytes, are mediators of immunosuppression in cancer, and, thus, variants in genes encoding Treg cell immune molecules could be associated with ovarian cancer.MethodsIn a populati…

2016
International journal of epidemiology ·doi:10.1093/ije/dyw207

BackgroundIn vitro and observational epidemiological studies suggest that vitamin D may play a role in cancer prevention. However, the relationship between vitamin D and ovarian cancer is uncertain, with observational studies generating con…

2016
Gynecologic Oncology ·doi:10.1016/j.ygyno.2015.04.034

ObjectiveClinical genetic testing is commercially available for rs61764370, an inherited variant residing in a KRAS 3' UTR microRNA binding site, based on suggested associations with increased ovarian and breast cancer risk as well as with …